The aim of this early phase 1/2 study is to obtain initial findings regarding safety and efficacy and to achieve rapid prioritization of new active substances for clinical application. The study will treat patients with newly diagnosed glioblastoma without MGMT promoter methylation after extensive molecular testing by assignment to a molecularly targeted therapy or by randomization to a control therapy or immunomodulatory therapy.